Keywords
Lung Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

299 Search results.

Eligibility Lung Neoplasms NCT01717482

- 7/11/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01717482

Eligibility Lung Neoplasms NCT01266512

- 7/11/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01266512

Eligibility Lung Neoplasms NCT01109524

- 7/10/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01109524

Eligibility Lung Carcinoma NCT02285660

- 7/10/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition; ODM derived from: https://clinicaltrials.gov/show/NCT02285660

Eligibility Lung Cancer NCT02115464

- 7/10/20 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02115464

Eligibility Lung Cancer NCT02134015

- 7/10/20 - 1 form, 2 itemgroups, 32 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung); ODM derived from: https://clinicaltrials.gov/show/NCT02134015

Eligibility Lung Cancer NCT01594398

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01594398

Eligibility Lung Cancer NCT01562028

- 7/8/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01562028

Eligibility Lung Cancer NCT01514877

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01514877

Eligibility Lung Cancer NCT00832715

- 7/8/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00832715

Eligibility Lung Cancer NCT01503385

- 7/8/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01503385

Eligibility Lung Cancer NCT00955695

- 7/7/20 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: Criteria
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00955695